By: Sourav Choudhary
Gilead Sciences has finalized its acquisition of CymaBay Therapeutics for an estimated total equity value of $4.3 billion. This acquisition includes CymaBay's l
Sourav Choudhary is a correspondent and web developer for The Enterprise. With a focus on business and finance, Sourav covers a wide range of topics including corporate news, market trends, and technological advancements. With a knack for delivering concise and informative articles, Sourav provides valuable insights to readers in the ever-changing world of business.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
This information evolves through artificial intelligence and human feedback. Improve this profile .